AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of May 21, 2026, ABCL trades at $4.58 with a market cap of $1.27B and a P/E ratio of -9.37. ABCL moved +12.72% today. Year to date, ABCL is +33.24%; over the trailing twelve months it is +118.66%. Its 52-week range spans $1.89 to $6.52. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AbCellera Biologics Inc. Common Shares (ABCL) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ABCL moved +12.72% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $4.58 |
| Market Cap | $1.27B |
| P/E Ratio | -9.37 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.52 |
| 52-Week Low | $1.89 |
| Volume | 90.15K |
| Avg Volume | 0 |
| Revenue (TTM) | $79.21M |
| Net Income | $-143.96M |
| Gross Margin | 0.00% |
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.